FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2247248684> ?p ?o ?g. }

• W2247248684 endingPage "e16023" @default.
• W2247248684 startingPage "e16023" @default.
• W2247248684 abstract "e16023 Background: Patients with LAH&NSCC caused by the human papillomavirus (HPV) have higher survival rates when treated with induction chemotherapy or concurrent cisplatin chemoradiotherapy. No previous report has shown whether these findings apply to patients treated with concurrent cetuximab (C) and radiation (XRT). Past research has found no difference in epidermal growth factor receptor (EGFR) expression in HPV+ tumors, but none have investigated differences in EGFR pathway activation by HPV status. Methods: Tumors from sequential patients treated with C and XRT were analyzed for HPV status using PCR for the E6/E7 gene sequence unique to HPV 16 or 18. Differences in overall survival (OS) and progression-free survival (PFS) were assessed by HPV status, stage, tumor (T) and nodal (N) status, primary site, and duration of XRT using the log rank test. Expression of pEGFR, pAkt, pPI3K, and pERK were measured and correlated with HPV status. Results: Between 1/07 and 11/09, 20 patients were treated with C + IMRT XRT. Primary sites included oral cavity (1), oropharynx (12), hypopharynx (1), larynx (5), and unknown (1). Six patients had stage III disease and 14 had IVa disease. Median age was 63 yrs (range 31 – 78). Median duration of XRT was 59 days (49-73). Median cycles of C was 7 (range 4 – 8). Six patients were HPV+, all were HPV16, all had oropharynx primaries, with a median age of 64 yrs. After a 19.0 mos. median follow up, 4 patients have died and 12 patients had disease progression. No correlation was found between OS or PFS and stage, T or N status, primary site, or XRT duration. For OS, 1-year and 2-year rates were 100% vs. 81% and 100% vs. 71% for HPV+ vs. HPV- tumors, respectively (p=0.11). For PFS, 1-year and 2-year rates were 100% vs. 31% and 60% vs. 31% (p=0.07). Differences in EGFR pathway activation and updated outcomes will be presented. Conclusions: Trends in improved OS and PFS by HPV status were seen in this small patient population treated with C. These findings are consistent with previous reports that HPV+ disease has a better prognosis no matter the treatment modality. Optimizing and personalizing therapy by HPV status remains the pivotal clinical research question in LAH&NSCC. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Bristol-Myers Squibb" @default.
• W2247248684 created "2016-06-24" @default.
• W2247248684 creator A5010002563 @default.
• W2247248684 creator A5018047271 @default.
• W2247248684 creator A5021668491 @default.
• W2247248684 creator A5023465873 @default.
• W2247248684 creator A5025424844 @default.
• W2247248684 creator A5030650037 @default.
• W2247248684 creator A5044236447 @default.
• W2247248684 creator A5054331664 @default.
• W2247248684 creator A5064623376 @default.
• W2247248684 creator A5079351118 @default.
• W2247248684 date "2010-05-20" @default.
• W2247248684 modified "2023-09-27" @default.
• W2247248684 title "Improved outcomes in HPV+ versus HPV- locally advanced head and neck squamous cell carcinoma (LAH&NSCC) when treated with cetuximab and concurrent radiation." @default.
• W2247248684 doi "https://doi.org/10.1200/jco.2010.28.15_suppl.e16023" @default.
• W2247248684 hasPublicationYear "2010" @default.
• W2247248684 type Work @default.
• W2247248684 sameAs 2247248684 @default.
• W2247248684 citedByCount "0" @default.
• W2247248684 crossrefType "journal-article" @default.
• W2247248684 hasAuthorship W2247248684A5010002563 @default.
• W2247248684 hasAuthorship W2247248684A5018047271 @default.
• W2247248684 hasAuthorship W2247248684A5021668491 @default.
• W2247248684 hasAuthorship W2247248684A5023465873 @default.
• W2247248684 hasAuthorship W2247248684A5025424844 @default.
• W2247248684 hasAuthorship W2247248684A5030650037 @default.
• W2247248684 hasAuthorship W2247248684A5044236447 @default.
• W2247248684 hasAuthorship W2247248684A5054331664 @default.
• W2247248684 hasAuthorship W2247248684A5064623376 @default.
• W2247248684 hasAuthorship W2247248684A5079351118 @default.
• W2247248684 hasConcept C121608353 @default.
• W2247248684 hasConcept C126322002 @default.
• W2247248684 hasConcept C143998085 @default.
• W2247248684 hasConcept C146357865 @default.
• W2247248684 hasConcept C151730666 @default.
• W2247248684 hasConcept C2776530083 @default.
• W2247248684 hasConcept C2776694085 @default.
• W2247248684 hasConcept C2776833033 @default.
• W2247248684 hasConcept C2778424827 @default.
• W2247248684 hasConcept C2779438470 @default.
• W2247248684 hasConcept C2779998722 @default.
• W2247248684 hasConcept C509974204 @default.
• W2247248684 hasConcept C526805850 @default.
• W2247248684 hasConcept C71924100 @default.
• W2247248684 hasConcept C86803240 @default.
• W2247248684 hasConcept C90924648 @default.
• W2247248684 hasConceptScore W2247248684C121608353 @default.
• W2247248684 hasConceptScore W2247248684C126322002 @default.
• W2247248684 hasConceptScore W2247248684C143998085 @default.
• W2247248684 hasConceptScore W2247248684C146357865 @default.
• W2247248684 hasConceptScore W2247248684C151730666 @default.
• W2247248684 hasConceptScore W2247248684C2776530083 @default.
• W2247248684 hasConceptScore W2247248684C2776694085 @default.
• W2247248684 hasConceptScore W2247248684C2776833033 @default.
• W2247248684 hasConceptScore W2247248684C2778424827 @default.
• W2247248684 hasConceptScore W2247248684C2779438470 @default.
• W2247248684 hasConceptScore W2247248684C2779998722 @default.
• W2247248684 hasConceptScore W2247248684C509974204 @default.
• W2247248684 hasConceptScore W2247248684C526805850 @default.
• W2247248684 hasConceptScore W2247248684C71924100 @default.
• W2247248684 hasConceptScore W2247248684C86803240 @default.
• W2247248684 hasConceptScore W2247248684C90924648 @default.
• W2247248684 hasIssue "15_suppl" @default.
• W2247248684 hasLocation W22472486841 @default.
• W2247248684 hasOpenAccess W2247248684 @default.
• W2247248684 hasPrimaryLocation W22472486841 @default.
• W2247248684 hasRelatedWork W1956415942 @default.
• W2247248684 hasRelatedWork W1996158748 @default.
• W2247248684 hasRelatedWork W2000204434 @default.
• W2247248684 hasRelatedWork W2020319882 @default.
• W2247248684 hasRelatedWork W2037602535 @default.
• W2247248684 hasRelatedWork W2047962734 @default.
• W2247248684 hasRelatedWork W2062707457 @default.
• W2247248684 hasRelatedWork W2110125130 @default.
• W2247248684 hasRelatedWork W3012537123 @default.
• W2247248684 hasRelatedWork W2182278658 @default.
• W2247248684 hasVolume "28" @default.
• W2247248684 isParatext "false" @default.
• W2247248684 isRetracted "false" @default.
• W2247248684 magId "2247248684" @default.
• W2247248684 workType "article" @default.